ArticleJournal of inflammation research2025
Kushe Tincture Ameliorates DNCB-Induced Atopic Dermatitis by Affecting NF-Kb/JAK-STAT3 Pathway: Bioinformatics Analysis and Animal Experiment Verification.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kushe tincture (KSD), an optimized in-hospital preparation of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, has been clinically used as an anti-inflammatory and anti-itching topical therapeutic drug for the treatment of eczema, atopic dermatitis (AD) and so on for decades. However, the potential therapeutic mechanisms remained unexplored. Objective: This study aimed to explore the mechanisms underlying the therapeutic effects of KSD against DNCB-induced AD through the combination of single-cell RNA sequencing (scRNA-seq), spatial transcriptomics (ST), and animal experiments. Methods: Firstly, we collected the active components and targets of KSD from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and obtained AD-associated targets from the Gene Expression Omnibus (GEO) database. Protein-protein interaction (PPI) networks were constructed using Cytoscape with Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Secondly, core targets were screened and visualized by scRNA-seq and ST technology. Finally, we adopted DNCB-induced AD-like mouse model to observe the therapeutic effect of KSD through lesion scoring, morphological staining, serological tests, skin barrier function measurements, flow cytometry, and Western blotting. Results: Forty-six common drug-disease targets were obtained and top 2 ranked targets were chosen, namely NF-kB1 and STAT3. Combined scRNA-seq and ST suggested that NF-KB and STAT3 had higher and wider expression in most subpopulations, especially in monocytes and CD4+ T-cells. Animal experiments showed that KSD treatment improved the visible symptoms and skin barrier function and decreased mast cell infiltration, IgE levels, Th17 cells, and expression of NF-kB, JAK2, and STAT3. Conclusion: KSD has therapeutic effects on DNCB-induced AD-like skin lesions, and it has effects on NF-kB and JAK-STAT3 proteins, which may be possible targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.